The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
 
Lauren Julia Brown
No Relationships to Disclose
 
Alison Weppler
No Relationships to Disclose
 
Prachi Bhave
No Relationships to Disclose
 
Clara Allayous
No Relationships to Disclose
 
James Randall Patrinely
No Relationships to Disclose
 
Patrick Alexander Ott
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Merck; Novartis; Pfizer
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Neon Therapeutics (Inst); Pfizer (Inst)
Expert Testimony - Boehringer Ingelheim
 
Shahneen Kaur Sandhu
Honoraria - Amgen; Bristol-Myers Squibb; Merck; Merck Serono
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Andrew Mark Haydon
Honoraria - Merck; Novartis
Consulting or Advisory Role - Novartis; Pierre Fabre
Speakers' Bureau - Merck; Novartis
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
Other Relationship - Avantis Medical Systems
 
Douglas Buckner Johnson
Consulting or Advisory Role - Array Biopharma; Bristol-Myers Squibb; Incyte; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
Travel, Accommodations, Expenses - Genentech
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Bristol-Myers Squibb; GlaxoSmithKline UK Ltd.; Hexal; MERCK; Novartis; OncoSec; Pierre Fabre; Roche
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; IDEAYA Biosciences; MSD; Novartis; Pierre Fabre; Roche